Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients |
Effi, Ahoua B
(Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University)
Aman, N'guiessan A (Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University) Koui, Baumaney S (Treichville Teaching Hospital) Koffi, Kouadio D (Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University) Traore, Zie C (Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University) Kouyate, Mohamed (Treichville Teaching Hospital) |
1 | Hammond ME, Hayes DF, Dowsett M, et al (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med, 134, 907-22. |
2 | Knight WA 3rd, Osborne CK, McGuire WL (1980). Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab, 9, 361-8. DOI |
3 | Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52. DOI |
4 | Joensuu K, Leidenius M, Kero M, et al (2013). ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancerreduced CK5 expression in metastases. Breast Cancer, 7, 23-34. |
5 | Kurian AW, Fish K, Shema SJ, Clarke CA (2010). Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res, 12, 99. DOI |
6 | Lakhani SR, Van De Vijver MJ, Jacquemier J, et al (2002). The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol, 20, 2310-2318. DOI |
7 | Lowery AJ, Miller N, Devaney A, et al (2009). MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res, 11, 27. |
8 | Lin CH, Liau JY, Lu YS, et al (2009). Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev, 18, 1807-14. DOI |
9 | Ly M, Antoine M, Dembélé AK, et al (2012). High incidence of triple-negative tumors in Sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncol 83, 257-63. DOI |
10 | Kwan ML, Kushi LH, Weltzien E, et al (2009). Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res, 11, 31. |
11 | Malone KE, Daling JR, Doody DR, et al (2006). Prevalence and predictors of BRCA1 and BRCA2 mutations in a population based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res, 66, 8297-308. DOI |
12 | Millikan RC, Newman B, Tse C-K, et al (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39. DOI |
13 | Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74. DOI |
14 | Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res, 7, 4-13. DOI |
15 | Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52. DOI |
16 | Pusztai L, Ayers M, Stec J, et al (2003). Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res, 9, 2406-15. |
17 | Pal T, Bonner D, Cragun D, et al (2015). A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer, 121, 4173-80. DOI |
18 | Parise CA, Bauer KR, Brown MM, Caggiano V (2009). Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J, 15, 593-602. DOI |
19 | Phipps AI, Chlebowski RT, Prentice R, et al (2011). Reproductive history and oral contraceptive use in relation to risk of triplenegative breast cancer. J Natl Cancer Inst, 103, 470-7. DOI |
20 | Parise CA, Caggiano V (2014). Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. |
21 | Ronnov-Jessen L, Petersen OW, Bissell MJ (1996). Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev, 76, 69-125. DOI |
22 | Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. DOI |
23 | Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100, 8418-23. DOI |
24 | Stark A, Kleer CG, Martin I, et al (2010). African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer, 16, 4926-32. |
25 | Stewart WB, Wild PC (2014). World cancer report. 3rd ed. Lyon: IARC. |
26 | Werner M, Chott A, Fabiano A, Battifora H (2000). Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol, 24, 1016-9. DOI |
27 | Seshie B, Adu-Aryee NA, Dedey F, et al (2015). A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol, 15, 14. DOI |
28 | Trivers KF, Lund MJ, Porter PL, et al (2009). The epidemiology of triple-negative breast cancer, including race. CCC, 20, 1071-82. |
29 | Tesfamariam A, Roy I (2013). Molecular biology of breast cancer in the horn of africa: case series-a pilot study of breast cancer from eritrea. ISRN Pathol. |
30 | Weigelt B, Horlings HM, Kreike B, et al (2008). Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol, 216, 141-50. DOI |
31 | Weigel MT, Dowsett M (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer, 17, 245-62. DOI |
32 | Wolff AC, Hammond ME, Hicks DG, et al (2013). American society of clinical oncology/college of american pathologists. recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol, 31, 3997-4013. DOI |
33 | Blows FM, Driver KE, Schmidt MK, et al (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 7, 1000279. DOI |
34 | Adebamowo CA, Famooto A, Ogundiran TO, et al (2008). Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat, 110, 183-8 . DOI |
35 | Ambrosone CB, Zirpoli G, Ruszczyk M, et al (2014). Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study. Cancer Causes Control, 25, 259-65. DOI |
36 | Byar DP, Sears ME, McGuire WL (1979). Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer, 15, 299-310. DOI |
37 | Bauer K, Parise C, Caggiano V (2010). Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer, 10, 228. DOI |
38 | Beltjens F, Bertaut A, Pigeonnat S, et al (2015). HER2- positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable. Eur J Cancer Care, DETAILS? |
39 | Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA, 295, 2492-502. DOI |
40 | Coulibaly JD, Effi AB, Horo GA, et al (2008). Hormonal status and overexpression of HER2 in breast cancer, Cancerology department of Treichville UHC. Preliminary results. Bull Cancer, 95, 799-803. |
41 | Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathol, 19, 403-10. DOI |
42 | Fouad A, Yousra A, Kaoutar Z, et al (2012). Molecular Classification of breast cancer in Morocco. Pan Afr Med J, 13, 9. |
43 | Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr. Assessed 25 Oct 2015. |
44 | Gullick WJ, Srinivasan R (1998). The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat, 52, 43-53. DOI |
45 | Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS (2009). Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med, 13, 4090-103. DOI |
46 | Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A (2014). Molecular breast cancer subtypes prevalence in an indigenous Sub-Saharan African population. Pan Afr Med J, 17, 249. |
47 | Huo D, Ikpatt F, Khramtsov A, et al (2009). Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. J Clin Oncol, 27, 4515-2. DOI |